Securities and Exchange Commission
Washington, D.C. 20549
Form 6-K
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d/16
of the Securities Exchange Act of 1934
August 2014
AEGON N.V.
Aegonplein 50
2591 TV THE HAGUE
The Netherlands
Aegon’s condensed consolidated interim financial statements Q2 2014, dated August 14, 2014, are included as appendix and incorporated herein by reference.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AEGON N.V. | ||||||
| (Registrant) | ||||||
| Date: August 14, 2014 | By | /s/ J.H.P.M. van Rossum | ||||
| J.H.P.M. van Rossum | ||||||
| Executive Vice President Corporate Controller | ||||||
| 2 | ||||
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 | ||||
| Notes to the condensed consolidated interim financial statements |
7 | |||
| Unaudited | 1 |
Amounts for 2013 have been restated for the voluntary changes in accounting policies for deferred policy acquisition costs and longevity reserving. Refer to note 2.1 for details about these changes.
| 2 | Unaudited |
Amounts for 2013 have been restated for the voluntary changes in accounting policies for deferred policy acquisition costs and longevity reserving. Refer to note 2.1 for details about these changes.
| Unaudited | 3 |
Amounts for 2013 have been restated for the voluntary changes in accounting policies for deferred policy acquisition costs and longevity reserving. Refer to note 2.1 for details about these changes.
| 4 | Unaudited |
| 1 | For a breakdown of share capital please refer to note 14. |
| 2 | Issued capital and reserves attributable to equity holders of Aegon N.V. |
Amounts for 2013 have been restated for the voluntary changes in accounting policies for deferred policy acquisition costs and longevity reserving. Refer to note 2.1 for details about these changes.
| Unaudited | 5 |
| 6 | Unaudited |
Notes to the Condensed Consolidated Interim Financial Statements
Amounts in EUR millions, unless otherwise stated
Aegon N.V., incorporated and domiciled in the Netherlands, is a public limited liability company organized under Dutch law and recorded in the Commercial Register of The Hague under number 27076669 and with its registered address at Aegonplein 50, 2591 TV, The Hague, the Netherlands. Aegon N.V. serves as the holding company for the Aegon Group and has listings of its common shares in Amsterdam and New York.
Aegon N.V. (or “the company”) and its consolidated subsidiaries (“Aegon” or “the Group”) have life insurance and pensions operations in over twenty countries in the Americas, Europe and Asia and are also active in savings and asset management operations, accident and health insurance, general insurance and to a limited extent banking operations. Its headquarters are located in The Hague, the Netherlands. The Group employs nearly 28,000 people worldwide.
1. Basis of presentation
The condensed consolidated interim financial statements as at, and for the six months ended, June 30, 2014, have been prepared in accordance with IAS 34 “Interim Financial Reporting”, as adopted by the European Union (hereafter “IFRS”). They do not include all of the information required for a full set of financial statements prepared in accordance with IFRS and should therefore be read together with the 2013 consolidated financial statements of Aegon N.V. as included in Aegon’s Annual Report for 2013 and the disclosures provided in note 2.1 and 2.2 of this report which disclose the impact of voluntary changes in accounting policies that were made by Aegon effective January 1, 2014. Aegon’s Annual Report for 2013 is available on its website (aegon.com).
The condensed consolidated interim financial statements have been prepared in accordance with the historical cost convention as modified by the revaluation of investment properties and those financial instruments (including derivatives) and financial liabilities that have been measured at fair value. Certain amounts in prior periods have been reclassified to conform to the current year presentation. These reclassifications had no effect on net income, shareholders’ equity or earnings per share. The condensed consolidated interim financial statements as at, and for the six months ended, June 30, 2014, were approved by the Executive Board on August 13, 2014.
The condensed consolidated interim financial statements are presented in euro and all values are rounded to the nearest million unless otherwise stated. The consequence is that the rounded amounts may not add up to the rounded total in all cases.
The published figures in these condensed consolidated interim financial statements are unaudited.
2. Significant accounting policies
All accounting policies and methods of computation applied in the condensed consolidated interim financial statements are the same as those applied in the 2013 consolidated financial statements, except for the newly applied accounting policies as described in note 2.1 and 2.2.
New IFRS accounting standards effective
The following standards, interpretations, amendments to standards and interpretations became effective in 2014:
| t | IFRS 10 Consolidated Financial Statements – Amendment Investment Entities; |
| t | IAS 36 Impairment of Assets – Recoverable Amounts Disclosures for Non-Financial Assets; and |
| t | IAS 39 – Novation of Derivatives and Continuation of Hedge Accounting. |
None of these new or revised standards and interpretations had a significant effect on the condensed consolidated interim financial statements for the period ended June 30, 2014.
| Unaudited | 7 |
For a complete overview of IFRS standards, published before January 1, 2014, that will be applied in future years, but were not early adopted by the Group, please refer to Aegon’s Annual Report for 2013.
Taxes
Taxes on income for the six months interim period, ending June 30, 2014, are accrued using the tax rate that would be applicable to expected total annual earnings.
Judgments and critical accounting estimates
Preparing the condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions, including the likelihood, timing or amount of future transactions or events, that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from the estimates made.
In preparing the condensed consolidated interim financial statements, significant judgments made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended December 31, 2013.
Exchange rates
Assets and liabilities are translated at the closing rates on the balance sheet date. Income, expenses and capital transactions (such as dividends) are translated at average exchange rates or at the prevailing rates on the transaction date, if more appropriate. The following exchange rates are applied for the condensed consolidated interim financial statements:
Closing exchange rates
| USD | GBP | |||||||||||||||
| June 30, 2014 |
1 | EUR | 1.3692 | 0.8008 | ||||||||||||
| December 31, 2013 |
1 | EUR | 1.3780 | 0.8320 |
Weighted average exchange rates
| USD | GBP | |||||||||||||||
| Six months ended June 30, 2014 |
1 | EUR | 1.3704 | 0.8212 | ||||||||||||
| Six months ended June 30, 2013 |
1 | EUR | 1.3124 | 0.8502 |
| 8 | Unaudited |
2.1 Voluntary changes in accounting policies
Aegon adopted voluntary changes in accounting policies, effective January 1, 2014, which are applied retrospectively for all periods presented in this document, both in the main schedules and the associated footnotes. Changes to these policies relate to deferred policy acquisition costs and how Aegon accounts for longevity trends in The Netherlands. In the paragraphs below, details are provided for these changes in accounting policies.
Deferred policy acquisition costs
Aegon adopted a single group-wide accounting policy for deferred policy acquisition costs as of January 1, 2014. Upon initial adoption of IFRS, entities were permitted to continue existing accounting policies for insurance contracts even though such policies were often non-uniform between countries. Through adoption of a uniform, group-wide accounting policy, Aegon eliminates this lack of uniformity for the deferral of policy acquisition costs thereby providing the users of the financial statements with more meaningful information.
IFRS 4 neither prohibits nor requires the deferral of policy acquisition costs, nor does it prescribe what acquisition costs are deferrable. Thus, in developing the new policy, Aegon considered and sought alignment with the proposed description of deferrable policy acquisition costs within the IFRS Insurance Contracts Phase II exposure draft (Exposure Draft). In the absence of detailed guidance in the Exposure Draft, Aegon also considered the recently adopted guidance in U.S. GAAP (ASU 2010-26 “Accounting for Costs Associated with Acquiring or Renewing Insurance Contracts”), if not conflicting with IFRS 4 or the Exposure Draft. IFRS currently differs from US GAAP by not limiting the deferral to expenses from successful efforts only and in the detail of how that principle is applied. Under the new accounting policy, deferred policy acquisition costs include costs that are directly attributable to the acquisition or renewal of insurance contracts. The previous accounting policy was based on a broader definition of costs that could be deferred.
Details of the impact of applying this voluntary change to previous periods are provided in the tables presented in note 2.2.
Longevity reserving
As of January 1, 2014, Aegon amended its policy to determine the insurance contract liability of Aegon The Netherlands to account for longevity risk assumed by Aegon. This change will provide more current information about the financial effects of changes in life expectancy of the insured population. The change will also increase alignment with market pricing of longevity risk. It will supply users of the financial statements with more relevant decision making information on the insurance contract liability and will improve transparency on the longevity risks assumed by Aegon.
Mortality tables will be updated annually based on the prospective tables taking into account longevity trends. The new methodology will take into account the contractual cash flows related to the longevity risk assumed. Previously the methodology applied by Aegon The Netherlands considered realized mortalities based on retrospective mortality tables.
Details of the impact of applying this voluntary change to previous periods are provided in the tables presented in note 2.2.
| Unaudited | 9 |
2.2 Impact of voluntary changes in accounting policies
| Impact of voluntary changes in accounting policies on consolidated income statement
|
||||||||||||||||
| YTD 2013 (previously reported) |
Change in accounting policy | YTD 2013 (restated) |
||||||||||||||
| Deferred policy acquisition costs |
Longevity reserving |
|||||||||||||||
| EUR millions | ||||||||||||||||
| Benefits and expenses |
22,200 | 36 | (53 | ) | 22,183 | |||||||||||
| Income tax (expense) / benefit |
(64 | ) | 11 | (11 | ) | (64 | ) | |||||||||
| Net effect |
(25 | ) | 42 | |||||||||||||
| Earnings per share (EUR per share) |
||||||||||||||||
| Basic earnings per common share |
0.15 | - | 0.01 | 0.16 | ||||||||||||
| Basic earnings per common share B |
- | - | - | - | ||||||||||||
| Diluted earnings per common share |
0.15 | - | 0.01 | 0.16 | ||||||||||||
| Diluted earnings per common share B |
- | - | - | - | ||||||||||||
| Earnings per common share calculation |
||||||||||||||||
| Net income attributable to equity holders of Aegon N.V. |
446 | (25 | ) | 42 | 463 | |||||||||||
| Preferred dividend |
(83 | ) | - | - | (83 | ) | ||||||||||
| Coupons on other equity instruments |
(69 | ) | - | - | (69 | ) | ||||||||||
| Earnings attributable to common shareholders |
294 | (25 | ) | 42 | 311 | |||||||||||
| Weighted average number of common shares outstanding (in million) |
1,978 | - | - | 1,978 | ||||||||||||
| Weighted average number of common shares B outstanding (in million) |
150 | - | - | 150 | ||||||||||||
| Impact
of voluntary changes in accounting policies on condensed consolidated statement of comprehensive
|
||||||||||||||||
| YTD 2013 (previously reported) |
Change in accounting policy | YTD 2013 (restated) |
||||||||||||||
| Deferred policy acquisition costs |
Longevity reserving |
|||||||||||||||
| EUR millions | ||||||||||||||||
| Net income |
447 | (25 | ) | 42 | 464 | |||||||||||
| Gains / (losses) on revaluation of available-for-sale investments |
(2,890 | ) | (30 | ) | - | (2,920 | ) | |||||||||
| Movement in foreign currency translation and net foreign investment hedging reserves |
(29 | ) | 48 | - | 19 | |||||||||||
| Income tax relating to items that may be reclassified |
981 | 11 | - | 992 | ||||||||||||
| Net effect other comprehensive income for the period |
29 | - | ||||||||||||||
| Net effect comprehensive income |
4 | 42 | ||||||||||||||
| Total comprehensive income attributable to: |
||||||||||||||||
| Equity holders of Aegon N.V. |
(1,778 | ) | 4 | 42 | (1,732 | ) | ||||||||||
| Non-controlling interests |
(2 | ) | - | - | (2 | ) | ||||||||||
| 10 | Unaudited |
| Impact of changes in accounting policies on the consolidated statement of financial position
|
||||||||||||||||||||
| December 31, 2013 1) |
Change in accounting policy | Reclassification 2) | December 31, 2013 (restated) |
|||||||||||||||||
| Deferred policy acquisition costs |
Longevity reserving |
|||||||||||||||||||
| EUR millions |
||||||||||||||||||||
| Assets |
||||||||||||||||||||
| Intangible assets |
2,246 | 26 | - | - | 2,272 | |||||||||||||||
| Investments in joint ventures |
1,427 | (1 | ) | - | - | 1,426 | ||||||||||||||
| Reinsurance assets |
10,345 | (2 | ) | - | - | 10,344 | ||||||||||||||
| Other assets and receivables |
7,429 | 2 | - | 156 | 7,586 | |||||||||||||||
| Deferred expenses |
12,040 | (2,035 | ) | - | - | 10,006 | ||||||||||||||
| Equity and liabilities |
||||||||||||||||||||
| Shareholders’ equity |
19,966 | (1,533 | ) | (832 | ) | - | 17,601 | |||||||||||||
| Insurance contracts |
100,642 | 54 | 1,073 | - | 101,769 | |||||||||||||||
| Other liabilities |
22,487 | (531 | ) | (241 | ) | 156 | 21,871 | |||||||||||||
| 1 | As reported in Aegon’s Annual Report dated March 19, 2014. |
| 2 | As a result of the voluntary accounting changes the balance of the Dutch tax group as at December 31, 2013 changed from a deferred tax liability to a deferred tax asset. |
| Impact of voluntary changes in accounting policies on consolidated statement of changes in equity | ||||||||||||||||
| December 31, 2013 1) |
Change in accounting policy | December 31, 2013 (restated) |
||||||||||||||
| Deferred policy acquisition costs |
Longevity reserving |
|||||||||||||||
| EUR millions |
||||||||||||||||
| Share capital |
8,701 | - | - | 8,701 | ||||||||||||
| Retained earnings |
10,750 | (1,557 | ) | (832 | ) | 8,361 | ||||||||||
| Revaluation reserves |
2,998 | 26 | - | 3,023 | ||||||||||||
| Remeasurement of defined benefit plans |
(706 | ) | - | - | (706 | ) | ||||||||||
| Other reserves |
(1,777 | ) | (1 | ) | - | (1,778 | ) | |||||||||
| Shareholders’ equity |
19,966 | (1,533 | ) | (832 | ) | 17,601 | ||||||||||
| 1 | As reported in Aegon’s Annual Report dated March 19, 2014. |
| Unaudited | 11 |
3. Segment information
3.1 Income statement
| EUR millions | Americas | The Netherlands |
United Kingdom |
New Markets |
Holding and other activities |
Eliminations | Segment Total |
Joint associates eliminations |
Consolidated | |||||||||||||||||||||||||||
| Three months ended June 30, 2014 |
||||||||||||||||||||||||||||||||||||
| Underlying earnings before tax geographically |
331 | 131 | 32 | 62 | (42 | ) | - | 514 | - | 514 | ||||||||||||||||||||||||||
| Fair value items |
(118 | ) | (132 | ) | (13 | ) | 1 | - | - | (263 | ) | 1 | (262 | ) | ||||||||||||||||||||||
| Realized gains / (losses) on investments |
51 | 47 | 97 | 2 | - | - | 198 | (1 | ) | 197 | ||||||||||||||||||||||||||
| Impairment charges |
(6 | ) | (5 | ) | - | (15 | ) | - | - | (26 | ) | - | (26 | ) | ||||||||||||||||||||||
| Impairment reversals |
21 | 2 | - | - | - | - | 23 | - | 23 | |||||||||||||||||||||||||||
| Other income / (charges) |
(11 | ) | (5 | ) | 2 | 1 | (1 | ) | - | (14 | ) | (1 | ) | (15 | ) | |||||||||||||||||||||
| Run-off businesses |
(1 | ) | - | - | - | - | - | (1 | ) | - | (1 | ) | ||||||||||||||||||||||||
| Income before tax |
268 | 39 | 117 | 51 | (43 | ) | - | 432 | (1 | ) | 431 | |||||||||||||||||||||||||
| Income tax (expense) / benefit |
(51 | ) | (7 | ) | (27 | ) | (16 | ) | 13 | - | (88 | ) | 1 | (88 | ) | |||||||||||||||||||||
| Net income |
216 | 32 | 90 | 35 | (30 | ) | - | 343 | - | 343 | ||||||||||||||||||||||||||
| Inter-segment underlying earnings |
(42 | ) | (15 | ) | (14 | ) | 65 | 6 | ||||||||||||||||||||||||||||
| Revenues |
||||||||||||||||||||||||||||||||||||
| Life insurance gross premiums |
1,538 | 540 | 1,171 | 486 | (1 | ) | (18 | ) | 3,716 | (88 | ) | 3,628 | ||||||||||||||||||||||||
| Accident and health insurance |
454 | 39 | 14 | 35 | 1 | (1 | ) | 542 | (1 | ) | 541 | |||||||||||||||||||||||||
| General insurance |
- | 154 | - | 56 | - | - | 211 | (20 | ) | 191 | ||||||||||||||||||||||||||
| Total gross premiums |
1,991 | 734 | 1,186 | 577 | - | (20 | ) | 4,469 | (109 | ) | 4,360 | |||||||||||||||||||||||||
| Investment income |
798 | 684 | 608 | 60 | 80 | (79 | ) | 2,151 | (10 | ) | 2,140 | |||||||||||||||||||||||||
| Fee and commission income |
328 | 80 | 10 | 148 | - | (56 | ) | 509 | (22 | ) | 487 | |||||||||||||||||||||||||
| Other revenues |
- | - | - | - | 1 | - | 2 | - | 2 | |||||||||||||||||||||||||||
| Total revenues |
3,118 | 1,498 | 1,803 | 785 | 82 | (155 | ) | 7,131 | (142 | ) | 6,989 | |||||||||||||||||||||||||
| Inter-segment revenues |
4 | - | - | 71 | 80 | |||||||||||||||||||||||||||||||
| EUR millions | Americas | The Netherlands |
United Kingdom |
New Markets |
Holding and other activities |
Eliminations | Segment Total |
Joint associates eliminations |
Consolidated | |||||||||||||||||||||||||||
| Three months ended June 30, 2013 |
||||||||||||||||||||||||||||||||||||
| Underlying earnings before tax geographically |
341 | 102 | 24 | 49 | (34 | ) | (1 | ) | 481 | (5 | ) | 476 | ||||||||||||||||||||||||
| Fair value items |
(163 | ) | (36 | ) | - | (8 | ) | (79 | ) | - | (286 | ) | 12 | (274 | ) | |||||||||||||||||||||
| Realized gains / (losses) on investments |
29 | 23 | 28 | 1 | - | - | 81 | (1 | ) | 80 | ||||||||||||||||||||||||||
| Impairment charges |
(40 | ) | (14 | ) | (16 | ) | 4 | - | - | (66 | ) | - | (66 | ) | ||||||||||||||||||||||
| Impairment reversals |
9 | - | - | - | - | - | 9 | - | 9 | |||||||||||||||||||||||||||
| Other income / (charges) |
(1 | ) | (27 | ) | (51 | ) | 106 | - | - | 27 | (1 | ) | 26 | |||||||||||||||||||||||
| Run-off businesses |
15 | - | - | - | - | - | 15 | - | 15 | |||||||||||||||||||||||||||
| Income before tax |
190 | 48 | (15 | ) | 152 | (113 | ) | (1 | ) | 261 | 5 | 266 | ||||||||||||||||||||||||
| Income tax (expense) / benefit |
(41 | ) | (6 | ) | 10 | (12 | ) | 28 | - | (21 | ) | (5 | ) | (26 | ) | |||||||||||||||||||||
| Net income |
149 | 42 | (5 | ) | 140 | (85 | ) | (1 | ) | 240 | - | 240 | ||||||||||||||||||||||||
| Inter-segment underlying earnings |
(43 | ) | (14 | ) | (15 | ) | 64 | 8 | ||||||||||||||||||||||||||||
| Revenues |
||||||||||||||||||||||||||||||||||||
| Life insurance gross premiums |
1,546 | 616 | 1,814 | 369 | 1 | (19 | ) | 4,327 | (103 | ) | 4,224 | |||||||||||||||||||||||||
| Accident and health insurance |
452 | 49 | - | 37 | 2 | (2 | ) | 538 | (1 | ) | 537 | |||||||||||||||||||||||||
| General insurance |
- | 150 | - | 42 | - | - | 192 | (6 | ) | 186 | ||||||||||||||||||||||||||
| Total gross premiums |
1,998 | 815 | 1,814 | 448 | 3 | (21 | ) | 5,057 | (110 | ) | 4,947 | |||||||||||||||||||||||||
| Investment income |
855 | 549 | 602 | 60 | 87 | (89 | ) | 2,064 | (16 | ) | 2,048 | |||||||||||||||||||||||||
| Fee and commission income |
331 | 81 | 30 | 141 | - | (62 | ) | 521 | (20 | ) | 501 | |||||||||||||||||||||||||
| Other revenues |
2 | - | - | - | 1 | - | 3 | (1 | ) | 2 | ||||||||||||||||||||||||||
| Total revenues |
3,186 | 1,445 | 2,446 | 649 | 91 | (172 | ) | 7,645 | (147 | ) | 7,498 | |||||||||||||||||||||||||
| Inter-segment revenues |
5 | - | 1 | 76 | 90 | |||||||||||||||||||||||||||||||
| 12 | Unaudited |
| EUR millions | Americas | The Netherlands |
United Kingdom |
New Markets | Holding and other activities |
Eliminations | Segment Total |
Joint ventures and associates eliminations |
Consolidated | |||||||||||||||||||||||||||
| Six months ended June 30, 2014 |
||||||||||||||||||||||||||||||||||||
| Underlying earnings before tax geographically |
633 | 259 | 58 | 123 | (63 | ) | 1 | 1,012 | (8 | ) | 1,004 | |||||||||||||||||||||||||
| Fair value items |
(167 | ) | (167 | ) | (16 | ) | 8 | (36 | ) | - | (379 | ) | 5 | (373 | ) | |||||||||||||||||||||
| Realized gains / (losses) on investments |
60 | 131 | 113 | 4 | - | - | 308 | (1 | ) | 306 | ||||||||||||||||||||||||||
| Impairment charges |
(12 | ) | (9 | ) | - | (24 | ) | - | - | (45 | ) | - | (45 | ) | ||||||||||||||||||||||
| Impairment reversals |
31 | 4 | - | - | - | - | 35 | - | 35 | |||||||||||||||||||||||||||
| Other income / (charges) |
(8 | ) | (8 | ) | (2 | ) | (1 | ) | (1 | ) | - | (20 | ) | (1 | ) | (21 | ) | |||||||||||||||||||
| Run-off businesses |
13 | - | - | - | - | - | 13 | - | 13 | |||||||||||||||||||||||||||
| Income before tax |
550 | 211 | 154 | 109 | (101 | ) | 1 | 924 | (5 | ) | 919 | |||||||||||||||||||||||||
| Income tax (expense) / benefit |
(115 | ) | (35 | ) | (36 | ) | (32 | ) | 29 | - | (189 | ) | 5 | (184 | ) | |||||||||||||||||||||
| Net income |
435 | 175 | 118 | 77 | (71 | ) | 1 | 735 | - | 735 | ||||||||||||||||||||||||||
| Inter-segment underlying earnings |
(83 | ) | (29 | ) | (28 | ) | 130 | 10 | ||||||||||||||||||||||||||||
| Revenues |
||||||||||||||||||||||||||||||||||||
| Life insurance gross premiums |
3,026 | 2,039 | 2,391 | 859 | 1 | (36 | ) | 8,280 | (173 | ) | 8,107 | |||||||||||||||||||||||||
| Accident and health insurance |
871 | 170 | 29 | 90 | 2 | (2 | ) | 1,160 | (9 | ) | 1,151 | |||||||||||||||||||||||||
| General insurance |
- | 290 | - | 114 | - | - | 404 | (38 | ) | 367 | ||||||||||||||||||||||||||
| Total gross premiums |
3,897 | 2,498 | 2,420 | 1,064 | 3 | (38 | ) | 9,844 | (220 | ) | 9,625 | |||||||||||||||||||||||||
| Investment income |
1,601 | 1,320 | 1,072 | 113 | 158 | (156 | ) | 4,108 | (20 | ) | 4,088 | |||||||||||||||||||||||||
| Fee and commission income |
641 | 158 | 20 | 290 | - | (113 | ) | 995 | (42 | ) | 953 | |||||||||||||||||||||||||
| Other revenues |
1 | - | - | 1 | 2 | - | 4 | (1 | ) | 3 | ||||||||||||||||||||||||||
| Total revenues |
6,140 | 3,976 | 3,512 | 1,468 | 163 | (308 | ) | 14,952 | (283 | ) | 14,669 | |||||||||||||||||||||||||
| Inter-segment revenues |
8 | - | - | 141 | 159 | |||||||||||||||||||||||||||||||
| EUR millions | Americas | The Netherlands |
United Kingdom |
New Markets | Holding and other activities |
Eliminations | Segment Total |
Joint ventures and associates eliminations |
Consolidated | |||||||||||||||||||||||||||
| Six months ended June 30, 2013 |
||||||||||||||||||||||||||||||||||||
| Underlying earnings before tax geographically |
648 | 216 | 45 | 109 | (72 | ) | (1 | ) | 945 | (24 | ) | 921 | ||||||||||||||||||||||||
| Fair value items |
(388 | ) | (109 | ) | (3 | ) | (11 | ) | (54 | ) | - | (565 | ) | 28 | (537 | ) | ||||||||||||||||||||
| Realized gains / (losses) on investments |
75 | 86 | 29 | 3 | - | - | 193 | (1 | ) | 192 | ||||||||||||||||||||||||||
| Impairment charges |
(56 | ) | (22 | ) | (16 | ) | (6 | ) | - | - | (100 | ) | - | (100 | ) | |||||||||||||||||||||
| Impairment reversals |
25 | - | - | - | - | - | 25 | - | 25 | |||||||||||||||||||||||||||
| Other income / (charges) |
(6 | ) | (27 | ) | (46 | ) | 102 | - | - | 23 | (1 | ) | 22 | |||||||||||||||||||||||
| Run-off businesses |
5 | - | - | - | - | - | 5 | - | 5 | |||||||||||||||||||||||||||
| Income before tax |
303 | 144 | 9 | 197 | (126 | ) | (1 | ) | 526 | 2 | 528 | |||||||||||||||||||||||||
| Income tax (expense) / benefit |
(43 | ) | (21 | ) | 1 | (28 | ) | 29 | - | (62 | ) | (2 | ) | (64 | ) | |||||||||||||||||||||
| Net income |
260 | 123 | 10 | 169 | (97 | ) | (1 | ) | 464 | - | 464 | |||||||||||||||||||||||||
| Inter-segment underlying earnings |
(89 | ) | (28 | ) | (29 | ) | 131 | 15 | ||||||||||||||||||||||||||||
| Revenues |
||||||||||||||||||||||||||||||||||||
| Life insurance gross premiums |
3,091 | 2,631 | 3,546 | 719 | 1 | (38 | ) | 9,950 | (245 | ) | 9,705 | |||||||||||||||||||||||||
| Accident and health insurance |
896 | 172 | - | 95 | 4 | (4 | ) | 1,163 | (8 | ) | 1,155 | |||||||||||||||||||||||||
| General insurance |
- | 278 | - | 82 | - | - | 360 | (6 | ) | 354 | ||||||||||||||||||||||||||
| Total gross premiums |
3,987 | 3,081 | 3,546 | 896 | 5 | (42 | ) | 11,473 | (259 | ) | 11,214 | |||||||||||||||||||||||||
| Investment income |
1,696 | 1,097 | 1,182 | 125 | 171 | (172 | ) | 4,099 | (38 | ) | 4,061 | |||||||||||||||||||||||||
| Fee and commission income |
628 | 163 | 56 | 275 | - | (121 | ) | 1,001 | (34 | ) | 967 | |||||||||||||||||||||||||
| Other revenues |
3 | - | - | 1 | 2 | - | 6 | (2 | ) | 4 | ||||||||||||||||||||||||||
| Total revenues |
6,314 | 4,341 | 4,784 | 1,297 | 178 | (335 | ) | 16,579 | (333 | ) | 16,246 | |||||||||||||||||||||||||
| Inter-segment revenues |
10 | - | 1 | 149 | 175 | |||||||||||||||||||||||||||||||
Non-IFRS measures
For segment reporting purposes the following non-IFRS financial measures are included: underlying earnings before tax, income tax and income before tax. These non-IFRS measures are calculated by consolidating on a proportionate basis Aegon’s joint ventures and associated companies. Aegon believes that its non-IFRS measures provide meaningful information about the underlying results of Aegon’s business, including insight into the financial measures that Aegon’s senior management uses in managing the business.
Among other things, Aegon’s senior management is compensated based in part on Aegon’s results against targets using the non-IFRS measures presented here. While many other insurers in Aegon’s peer group present substantially similar non-IFRS measures, the non-IFRS measures presented in this document may nevertheless differ from the non-IFRS measures presented by other insurers. There is no standardized meaning to these measures under IFRS or any other recognized set of accounting standards. Readers are cautioned to consider carefully the different ways in which Aegon and its peers present similar information before comparing them.
| Unaudited | 13 |
Aegon believes the non-IFRS measures shown herein, when read together with Aegon’s reported IFRS financial statements, provide meaningful supplemental information for the investing public to evaluate Aegon’s business after eliminating the impact of current IFRS accounting policies for financial instruments and insurance contracts, which embed a number of accounting policies alternatives that companies may select in presenting their results (i.e. companies can use different local GAAPs to measure the insurance contract liability) and that can make the comparability from period to period difficult.
The reconciliation from underlying earnings before tax to income before tax, being the most comparable IFRS measure, is presented in the tables in this note.
Underlying earnings
Underlying earnings reflect our profit from underlying business operations and exclude components that relate to accounting mismatches that are dependent on market volatility or relate to events that are considered outside the normal course of business. Below we describe items that are excluded from underlying earnings.
Fair value items
Fair value items include the over- or underperformance of investments and guarantees held at fair value for which the expected long-term return is included in underlying earnings. Changes to these long-term return assumptions are also included in the fair value items.
In addition, hedge ineffectiveness on hedge transactions, fair value changes on economic hedges without natural offset in earnings and for which no hedge accounting is applied and fair value movements on real estate are included under fair value items.
Certain assets held by Aegon Americas, Aegon The Netherlands and Aegon UK are carried at fair value and managed on a total return basis, with no offsetting changes in the valuation of related liabilities. These include assets such as investments in hedge funds, private equities, real estate (limited partnerships), convertible bonds and structured products. Underlying earnings exclude any over- or underperformance compared to management’s long-term expected return on assets.
Based on current holdings and asset returns, the long-term expected return on an annual basis is 8-10%, depending on asset class, including cash income and market value changes. The expected earnings from these asset classes are net of deferred policy acquisition costs (“DPAC”) where applicable.
In addition, certain products offered by Aegon Americas contain guarantees and are reported on a fair value basis, including the segregated funds offered by Aegon Canada and the total return annuities and guarantees on variable annuities of Aegon USA. The earnings on these products are impacted by movements in equity markets and risk-free interest rates. Short-term developments in the financial markets may therefore cause volatility in earnings. Included in underlying earnings is a long-term expected return on these products and excluded is any over- or underperformance compared to management’s expected return.
The fair value movements of certain guarantees and the fair value change of derivatives that hedge certain risks on these guarantees of Aegon The Netherlands and Variable Annuities Europe (included in New Markets) are excluded from underlying earnings, and the long-term expected return for these guarantees is set at zero.
| 14 | Unaudited |
Holding and other activities include certain issued bonds that are held at fair value through profit or loss (“FVTPL”). The interest rate risk on these bonds is hedged using swaps. The fair value movement resulting from changes in Aegon’s credit spread used in the valuation of these bonds are excluded from underlying earnings and reported under fair value items.
Realized gains or losses on investments
Includes realized gains and losses on available-for-sale investments, mortgage loans and other loan portfolios.
Impairment charges/reversals
Includes impairments and reversals on available-for-sale debt securities and impairments on shares including the effect of deferred policyholder acquisition costs, mortgage loans and loan portfolios at amortized cost and associates respectively.
Other income or charges
Other income or charges is used to report any items which cannot be directly allocated to a specific line of business. Also items that are outside the normal course of business are reported under this heading.
Other charges include restructuring charges that are considered other charges for segment reporting purposes because they are outside the normal course of business. In the condensed consolidated interim financial statements, these charges are included in operating expenses.
Run-off businesses
Includes underlying results of business units where management has decided to exit the market and to run-off the existing block of business. Currently, this line includes the run-off of the institutional spread-based business, structured settlements blocks of business, Bank-Owned and Corporate-Owned Life Insurance (BOLI/COLI) business, and the sale of the life reinsurance business in the United States. Aegon has other blocks of business for which sales have been discontinued and of which the earnings are included in underlying earnings.
Share in earnings of joint ventures and associates
Earnings from Aegon’s joint ventures in Spain, China and Japan and Aegon’s associates in India, Brazil and Mexico are reported on an underlying earnings basis.
| Unaudited | 15 |
3.2 Investments geographically
Amounts included in the tables on investments geographically are presented on an IFRS-basis.
| amounts in million EUR (unless otherwise stated) | ||||||||||||||||||||||||||||||||||||
| Americas USD |
United Kingdom GBP |
June 30, 2014 | Americas | The Netherlands |
United Kingdom |
New Markets |
Holding & other activities |
Eliminations | Total EUR |
|||||||||||||||||||||||||||
| Investments | ||||||||||||||||||||||||||||||||||||
| 2,122 | 97 | Shares | 1,550 | 270 | 121 | 25 | 67 | (1 | ) | 2,031 | ||||||||||||||||||||||||||
| 81,357 | 9,036 | Debt securities | 59,419 | 20,867 | 11,284 | 3,373 | - | - | 94,943 | |||||||||||||||||||||||||||
| 10,940 | - | Loans | 7,990 | 26,134 | - | 487 | 10 | - | 34,622 | |||||||||||||||||||||||||||
| 11,327 | 352 | Other financial assets | 8,273 | 320 | 440 | 36 | 105 | - | 9,173 | |||||||||||||||||||||||||||
| 972 | - | Investments in real estate | 710 | 798 | - | 2 | - | - | 1,510 | |||||||||||||||||||||||||||
| 106,717 | 9,485 | Investments general account | 77,941 | 48,389 | 11,844 | 3,923 | 181 | (1 | ) | 142,278 | ||||||||||||||||||||||||||
| 1,779 | 12,683 | Shares | 1,300 | 9,070 | 15,838 | 361 | - | (10 | ) | 26,559 | ||||||||||||||||||||||||||
| 6,426 | 9,262 | Debt securities | 4,694 | 17,959 | 11,566 | 278 | - | - | 34,497 | |||||||||||||||||||||||||||
| 101,280 | 22,087 | Unconsolidated investment funds | 73,970 | - | 27,581 | 6,056 | - | - | 107,608 | |||||||||||||||||||||||||||
| 381 | 3,368 | Other financial assets | 278 | 393 | 4,206 | 14 | - | - | 4,892 | |||||||||||||||||||||||||||
| - | 828 | Investments in real estate | - | - | 1,035 | - | - | - | 1,035 | |||||||||||||||||||||||||||
| 109,867 | 48,229 | Investments for account of policyholders | 80,242 | 27,422 | 60,226 | 6,710 | - | (10 | ) | 174,590 | ||||||||||||||||||||||||||
| 216,584 | 57,714 | Investments on balance sheet | 158,183 | 75,811 | 72,071 | 10,633 | 181 | (11 | ) | 316,868 | ||||||||||||||||||||||||||
| 167,588 | 331 | Off balance sheet investments third parties | 122,398 | 920 | 414 | 62,813 | - | - | 186,545 | |||||||||||||||||||||||||||
| 384,172 | 58,046 | Total revenue generating investments | 280,582 | 76,730 | 72,485 | 73,446 | 181 | (11 | ) | 503,413 | ||||||||||||||||||||||||||
| Investments | ||||||||||||||||||||||||||||||||||||
| 88,400 | 9,340 | Available-for-sale | 64,564 | 20,792 | 11,663 | 3,391 | 10 | - | 100,419 | |||||||||||||||||||||||||||
| 10,940 | - | Loans | 7,990 | 26,134 | - | 487 | 10 | - | 34,622 | |||||||||||||||||||||||||||
| 116,272 | 47,546 | Financial assets at fair value through profit or loss | 84,919 | 28,086 | 59,373 | 6,754 | 162 | (11 | ) | 179,284 | ||||||||||||||||||||||||||
| 972 | 828 | Investments in real estate | 710 | 798 | 1,035 | 2 | - | - | 2,544 | |||||||||||||||||||||||||||
| 216,584 | 57,714 | Total investments on balance sheet | 158,183 | 75,811 | 72,071 | 10,633 | 181 | (11 | ) | 316,868 | ||||||||||||||||||||||||||
| 13 | - | Investments in joint ventures | 10 | 788 | - | 631 | - | - | 1,429 | |||||||||||||||||||||||||||
| 121 | 17 | Investments in associates | 88 | 19 | 21 | 371 | 2 | - | 501 | |||||||||||||||||||||||||||
| 30,078 | 4,150 | Other assets | 21,967 | 25,093 | 5,182 | 3,006 | 34,550 | (32,610 | ) | 57,189 | ||||||||||||||||||||||||||
| 246,796 | 61,881 | Consolidated total assets | 180,249 | 101,711 | 77,274 | 14,641 | 34,734 | (32,621 | ) | 375,988 | ||||||||||||||||||||||||||
| amounts in million EUR (unless otherwise stated) | ||||||||||||||||||||||||||||||||||||
| Americas USD |
United Kingdom GBP |
December 31, 2013 | Americas | The Netherlands |
United Kingdom |
New Markets |
Holding & other activities |
Eliminations | Total EUR |
|||||||||||||||||||||||||||
| Investments | ||||||||||||||||||||||||||||||||||||
| 2,007 | 46 | Shares | 1,456 | 447 | 55 | 45 | 36 | (2 | ) | 2,036 | ||||||||||||||||||||||||||
| 78,719 | 8,719 | Debt securities | 57,125 | 19,095 | 10,479 | 2,812 | - | - | 89,511 | |||||||||||||||||||||||||||
| 11,289 | 1 | Loans | 8,192 | 24,708 | 1 | 508 | - | - | 33,409 | |||||||||||||||||||||||||||
| 11,418 | 173 | Other financial assets | 8,286 | 293 | 208 | 30 | 103 | - | 8,920 | |||||||||||||||||||||||||||
| 993 | - | Investments in real estate | 721 | 810 | - | 1 | - | - | 1,532 | |||||||||||||||||||||||||||
| 104,425 | 8,938 | Investments general account | 75,780 | 45,354 | 10,743 | 3,396 | 139 | (2 | ) | 135,409 | ||||||||||||||||||||||||||
| 1,804 | 12,792 | Shares | 1,309 | 8,450 | 15,375 | 297 | - | (8 | ) | 25,423 | ||||||||||||||||||||||||||
| 6,675 | 9,643 | Debt securities | 4,844 | 16,791 | 11,590 | 307 | - | - | 33,531 | |||||||||||||||||||||||||||
| 94,950 | 21,776 | Unconsolidated investment funds | 68,905 | - | 26,173 | 5,744 | - | - | 100,822 | |||||||||||||||||||||||||||
| 230 | 3,062 | Other financial assets | 167 | 405 | 3,680 | 9 | - | - | 4,261 | |||||||||||||||||||||||||||
| - | 828 | Investments in real estate | - | - | 996 | - | - | - | 996 | |||||||||||||||||||||||||||
| 103,659 | 48,101 | Investments for account of policyholders | 75,224 | 25,646 | 57,813 | 6,357 | - | (8 | ) | 165,032 | ||||||||||||||||||||||||||
| 208,084 | 57,039 | Investments on balance sheet | 151,004 | 70,999 | 68,556 | 9,754 | 139 | (10 | ) | 300,441 | ||||||||||||||||||||||||||
| 155,179 | 239 | Off balance sheet investments third parties | 112,611 | 994 | 287 | 60,951 | - | - | 174,843 | |||||||||||||||||||||||||||
| 363,262 | 57,277 | Total revenue generating investments | 263,616 | 71,993 | 68,843 | 70,705 | 139 | (10 | ) | 475,285 | ||||||||||||||||||||||||||
| Investments | ||||||||||||||||||||||||||||||||||||
| 86,347 | 8,892 | Available-for-sale | 62,661 | 19,452 | 10,687 | 2,827 | 8 | - | 95,635 | |||||||||||||||||||||||||||
| 11,289 | 1 | Loans | 8,192 | 24,708 | 1 | 508 | - | - | 33,409 | |||||||||||||||||||||||||||
| 109,455 | 47,318 | Financial assets at fair value through profit or loss | 79,430 | 26,029 | 56,872 | 6,418 | 131 | (10 | ) | 168,870 | ||||||||||||||||||||||||||
| 993 | 828 | Investments in real estate | 721 | 810 | 996 | 1 | - | - | 2,528 | |||||||||||||||||||||||||||
| 208,084 | 57,039 | Total investments on balance sheet | 151,004 | 70,999 | 68,556 | 9,754 | 139 | (10 | ) | 300,441 | ||||||||||||||||||||||||||
| - | - | Investments in joint ventures | - | 819 | - | 607 | - | - | 1,426 | |||||||||||||||||||||||||||
| 112 | 16 | Investments in associates | 81 | 19 | 20 | 350 | 1 | - | 470 | |||||||||||||||||||||||||||
| 31,112 | 4,227 | Other assets | 22,577 | 17,067 | 5,080 | 2,936 | 29,869 | (28,103 | ) | 49,430 | ||||||||||||||||||||||||||
| 239,307 | 61,282 | Consolidated total assets | 173,663 | 88,903 | 73,656 | 13,647 | 30,008 | (28,113 | ) | 351,767 | ||||||||||||||||||||||||||
4. Premium income and premium to reinsurers
| EUR millions |
Q2 2014 | Q2 2013 | YTD 2014 | YTD 2013 | ||||||||||||
| Gross |
||||||||||||||||
| Life |
3,628 | 4,224 | 8,107 | 9,705 | ||||||||||||
| Non-Life |
732 | 723 | 1,518 | 1,509 | ||||||||||||
| Total |
4,360 | 4,947 | 9,625 | 11,214 | ||||||||||||
| Reinsurance |
||||||||||||||||
| Life |
675 | 694 | 1,319 | 1,365 | ||||||||||||
| Non-Life |
74 | 92 | 152 | 182 | ||||||||||||
| Total |
749 | 786 | 1,471 | 1,547 | ||||||||||||
| 16 | Unaudited |
5. Investment income
| EUR millions |
Q2 2014 | Q2 2013 | YTD 2014 | YTD 2013 | ||||||||||||
| Interest income |
1,682 | 1,705 | 3,379 | 3,396 | ||||||||||||
| Dividend income |
421 | 314 | 642 | 606 | ||||||||||||
| Rental income |
37 | 29 | 67 | 59 | ||||||||||||
| Total investment income |
2,140 | 2,048 | 4,088 | 4,061 | ||||||||||||
| Investment income related to general account |
1,406 | 1,413 | 2,801 | 2,797 | ||||||||||||
| Investment income for account of policyholders |
734 | 635 | 1,287 | 1,264 | ||||||||||||
| Total |
2,140 | 2,048 | 4,088 | 4,061 | ||||||||||||
6. Results from financial transactions
| EUR millions |
Q2 2014 | Q2 2013 | YTD 2014 | YTD 2013 | ||||||||||||
| Net fair value change of general account financial investments at FVTPL other than derivatives |
92 | (21 | ) | 161 | 123 | |||||||||||
| Realized gains and (losses) on financial investments |
198 | 75 | 307 | 188 | ||||||||||||
| Gains and (losses) on investments in real estate |
(9 | ) | (11 | ) | (14 | ) | (26 | ) | ||||||||
| Net fair value change of derivatives |
247 | (214 | ) | 336 | (479 | ) | ||||||||||
| Net fair value change on for account of policyholder financial assets at FVTPL |
3,921 | (2,281 | ) | 5,867 | 5,462 | |||||||||||
| Net fair value change on investments in real estate for account of policyholders |
21 | (23 | ) | 28 | (33 | ) | ||||||||||
| Net foreign currency gains and (losses) |
(18 | ) | 2 | (12 | ) | 4 | ||||||||||
| Net fair value change on borrowings and other financial liabilities |
(11 | ) | 14 | (4 | ) | 33 | ||||||||||
| Realized gains and (losses) on repurchased debt |
3 | (1 | ) | 3 | (1 | ) | ||||||||||
| Total |
4,444 | (2,460 | ) | 6,672 | 5,271 | |||||||||||
Net fair value change on for accounts of policyholder financial assets at FVTPL is offset by amounts in the Claims and benefits line reported in note 7 - Benefits and expenses.
7. Benefits and expenses
| EUR millions |
Q2 2014 | Q2 2013 | YTD 2014 | YTD 2013 | ||||||||||||
| Claims and benefits |
11,006 | 4,554 | 20,338 | 20,747 | ||||||||||||
| Employee expenses |
506 | 528 | 982 | 1,040 | ||||||||||||
| Administration expenses |
276 | 271 | 552 | 520 | ||||||||||||
| Deferred expenses |
(339 | ) | (344 | ) | (656 | ) | (658 | ) | ||||||||
| Amortization charges |
246 | 293 | 493 | 534 | ||||||||||||
| Total |
11,695 | 5,302 | 21,708 | 22,183 | ||||||||||||
Claims and benefits includes claims and benefits in excess of account value for products for which deposit accounting is applied and the change in valuation of liabilities for insurance and investment contracts. In addition, commissions and expenses and premium paid to reinsurers are included. Claims and benefits fluctuates mainly as a result of changes in technical provisions resulting from fair value changes on for account of policyholder financial assets included in Results from financial transactions (note 6).
| Unaudited | 17 |
8. Impairment charges/(reversals)
| EUR millions |
Q2 2014 | Q2 2013 | YTD 2014 | YTD 2013 | ||||||||||||
| Impairment charges / (reversals) comprise: |
||||||||||||||||
| Impairment charges on financial assets, excluding receivables 1 |
28 | 63 | 49 | 103 | ||||||||||||
| Impairment reversals on financial assets, excluding receivables 1 |
(23 | ) | (9 | ) | (35 | ) | (25 | ) | ||||||||
| Impairment charges / (reversals) on non-financial assets and receivables |
3 | (5 | ) | 1 | (4 | ) | ||||||||||
| Total |
8 | 49 | 16 | 74 | ||||||||||||
| Impairment charges on financial assets, excluding receivables, from: |
||||||||||||||||
| Shares |
2 | - | 3 | - | ||||||||||||
| Debt securities and money market instruments |
7 | 50 | 12 | 63 | ||||||||||||
| Loans |
19 | 13 | 35 | 40 | ||||||||||||
| Total |
28 | 63 | 49 | 103 | ||||||||||||
| Impairment reversals on financial assets, excluding receivables, from: |
||||||||||||||||
| Debt securities and money market instruments |
(20 | ) | (8 | ) | (29 | ) | (22 | ) | ||||||||
| Loans |
(3 | ) | (1 | ) | (5 | ) | (3 | ) | ||||||||
| Total |
(23 | ) | (9 | ) | (35 | ) | (25 | ) | ||||||||
1 Impairment charges / (reversals) on financial assets, excluding receivables, are excluded from underlying earnings before tax for segment reporting (refer to note 3).
9. Investments
| EUR millions |
Jun. 30, 2014 | Dec. 31, 2013 | ||||||
| Available-for-sale (AFS) |
100,419 | 95,635 | ||||||
| Loans |
34,622 | 33,409 | ||||||
| Financial assets at fair value through profit or loss (FVTPL) |
5,728 | 4,833 | ||||||
| Financial assets, excluding derivatives |
140,768 | 133,877 | ||||||
| Investments in real estate |
1,510 | 1,532 | ||||||
| Total investments for general account, excluding derivatives |
142,278 | 135,409 | ||||||
| Total financial assets, excluding derivatives
|
||||||||||||||||
| AFS | FVTPL | Loans | Total | |||||||||||||
| Shares |
672 | 1,359 | - | 2,031 | ||||||||||||
| Debt securities |
93,073 | 1,870 | - | 94,943 | ||||||||||||
| Money market and other short-term investments |
5,504 | 729 | - | 6,233 | ||||||||||||
| Mortgages loans |
- | - | 30,532 | 30,532 | ||||||||||||
| Private loans |
- | - | 1,806 | 1,806 | ||||||||||||
| Deposits with financial institutions |
- | - | 229 | 229 | ||||||||||||
| Policy loans |
- | - | 1,911 | 1,911 | ||||||||||||
| Other |
1,170 | 1,770 | 143 | 3,083 | ||||||||||||
| June 30, 2014 |
100,419 | 5,728 | 34,622 | 140,768 | ||||||||||||
| AFS | FVTPL | Loans | Total | |||||||||||||
| Shares |
787 | 1,250 | - | 2,036 | ||||||||||||
| Debt securities |
88,162 | 1,350 | - | 89,511 | ||||||||||||
| Money market and other short-term investments |
5,524 | 449 | - | 5,974 | ||||||||||||
| Mortgages loans |
- | - | 29,245 | 29,245 | ||||||||||||
| Private loans |
- | - | 1,783 | 1,783 | ||||||||||||
| Deposits with financial institutions |
- | - | 292 | 292 | ||||||||||||
| Policy loans |
- | - | 1,955 | 1,955 | ||||||||||||
| Other |
1,163 | 1,784 | 135 | 3,082 | ||||||||||||
| December 31, 2013 |
95,635 | 4,833 | 33,409 | 133,877 | ||||||||||||
| 18 | Unaudited |
10. Investments for account of policyholders
| EUR millions |
Jun. 30, 2014 | Dec. 31, 2013 | ||||||
| Shares |
26,559 | 25,423 | ||||||
| Debt securities |
34,497 | 33,531 | ||||||
| Money market and short-term investments |
959 | 850 | ||||||
| Deposits with financial institutions |
3,522 | 3,006 | ||||||
| Unconsolidated investment funds |
107,608 | 100,822 | ||||||
| Other |
410 | 404 | ||||||
| Total investments for account of policyholders at fair value through profit or loss, excluding derivatives |
173,556 | 164,037 | ||||||
| Investment in real estate |
1,035 | 996 | ||||||
| Total investments for account of policyholders |
174,590 | 165,032 | ||||||
11. Derivatives
The movements in derivative balances mainly result from changes in interest rates and other market movements during the period.
12. Fair value
The following tables provide an analysis of financial instruments recorded at fair value on a recurring basis by level of the fair value hierarchy:
| Fair value hierarchy |
||||||||||||||||
| EUR millions | Level I | Level II | Level III | Total | ||||||||||||
| As at June 30, 2014 |
||||||||||||||||
| Financial assets carried at fair value |
||||||||||||||||
| Available-for-sale investments |
||||||||||||||||
| Shares |
121 | 280 | 271 | 672 | ||||||||||||
| Debt securities |
22,808 | 66,965 | 3,299 | 93,073 | ||||||||||||
| Money markets and other short-term instruments |
- | 5,504 | - | 5,504 | ||||||||||||
| Other investments at fair value |
27 | 318 | 824 | 1,170 | ||||||||||||
| Total Available-for-sale investments |
22,956 | 73,068 | 4,395 | 100,419 | ||||||||||||
| Fair value through profit or loss |
||||||||||||||||
| Shares |
1,153 | 207 | - | 1,359 | ||||||||||||
| Debt securities |
94 | 1,745 | 30 | 1,870 | ||||||||||||
| Money markets and other short-term instruments |
95 | 634 | - | 729 | ||||||||||||
| Other investments at fair value |
1 | 575 | 1,195 | 1,770 | ||||||||||||
| Investments for account of policyholders 1 |
102,852 | 68,757 | 1,947 | 173,556 | ||||||||||||
| Derivatives |
12 | 19,626 | 299 | 19,937 | ||||||||||||
| Total Fair value through profit or loss |
104,207 | 91,544 | 3,471 | 199,221 | ||||||||||||
| Total financial assets at fair value |
127,163 | 164,611 | 7,865 | 299,639 | ||||||||||||
| Financial liabilities carried at fair value |
||||||||||||||||
| Investment contracts for account of policyholders 2 |
13,528 | 21,004 | 117 | 34,649 | ||||||||||||
| Borrowings 3 |
509 | 515 | - | 1,024 | ||||||||||||
| Derivatives |
31 | 15,588 | 1,913 | 17,532 | ||||||||||||
| Total financial liabilities at fair value |
14,068 | 37,107 | 2,030 | 53,205 | ||||||||||||
| Unaudited | 19 |
| Fair value hierarchy |
||||||||||||||||
| EUR millions | Level I | Level II | Level III | Total | ||||||||||||
| As at December 31, 2013 |
||||||||||||||||
| Financial assets carried at fair value |
||||||||||||||||
| Available-for-sale investments |
||||||||||||||||
| Shares |
202 | 262 | 322 | 787 | ||||||||||||
| Debt securities |
20,815 | 64,184 | 3,162 | 88,162 | ||||||||||||
| Money markets and other short-term instruments |
- | 5,524 | - | 5,524 | ||||||||||||
| Other investments at fair value |
25 | 312 | 826 | 1,163 | ||||||||||||
| Total Available-for-sale investments |
21,043 | 70,282 | 4,310 | 95,635 | ||||||||||||
| Fair value through profit or loss |
||||||||||||||||
| Shares |
1,120 | 130 | - | 1,250 | ||||||||||||
| Debt securities |
64 | 1,268 | 17 | 1,350 | ||||||||||||
| Money markets and other short-term instruments |
95 | 354 | - | 449 | ||||||||||||
| Other investments at fair value |
- | 567 | 1,217 | 1,784 | ||||||||||||
| Investments for account of policyholders 1 |
99,040 | 63,008 | 1,989 | 164,037 | ||||||||||||
| Derivatives |
69 | 13,134 | 328 | 13,531 | ||||||||||||
| Total Fair value through profit or loss |
100,388 | 78,461 | 3,552 | 182,401 | ||||||||||||
| Total financial assets at fair value |
121,431 | 148,744 | 7,862 | 278,036 | ||||||||||||
| Financial liabilities carried at fair value |
||||||||||||||||
| Investment contracts for account of policyholders 2 |
12,872 | 19,641 | 114 | 32,628 | ||||||||||||
| Borrowings 3 |
517 | 500 | - | 1,017 | ||||||||||||
| Derivatives |
24 | 10,383 | 1,431 | 11,838 | ||||||||||||
| Total financial liabilities at fair value |
13,413 | 30,524 | 1,545 | 45,482 | ||||||||||||
| 1 | The investments for account of policyholders included in the table above represents those investments carried at fair value through profit or loss. |
| 2 | The investment contracts for account of policyholders included in the table above represents those investment contracts carried at fair value. |
| 3 | Total borrowings on the statement of financial position contain borrowings carried at amortized cost that are not included in the above schedule. |
Significant transfers between Level I, Level II and Level III
Aegon’s policy is to record transfers of assets and liabilities between Level I, Level II and Level III at their fair values as of the beginning of each reporting period.
The table below shows transfers between Level I and II for financial assets and financial liabilities recorded at fair value on a recurring basis during the six-month period ended June 30, 2014.
| Fair value transfers | ||||||||||||||||
| EUR millions | YTD 2014 | Full Year 2013 | ||||||||||||||
| Transfers Level I to Level II |
Transfers Level II to Level I |
Transfers Level I to Level II |
Transfers Level II to |
|||||||||||||
| Financial assets carried at fair value available-for-sale investments |
||||||||||||||||
| Shares |
- | - | - | 1 | ||||||||||||
| Debt securities |
- | 43 | 1 | 209 | ||||||||||||
| Total |
- | 43 | 2 | 210 | ||||||||||||
| Fair value through profit or loss |
||||||||||||||||
| Investments for account of policyholders |
- | 1 | - | 263 | ||||||||||||
| Total |
- | 1 | - | 263 | ||||||||||||
| Total financial assets at fair value |
- | 43 | 2 | 473 | ||||||||||||
Transfers are identified based on transaction volume and frequency, which are indicative of an active market.
| 20 | Unaudited |
Movements in Level III financial instruments measured at fair value
The following table summarizes the change of all assets and liabilities measured at estimated fair value on a recurring basis using significant unobservable inputs (Level III), including realized and unrealized gains (losses) of all assets and liabilities and unrealized gains (losses) of all assets and liabilities still held at the end of the respective period.
| Roll forward of Level III financial instruments | ||||||||||||||||||||||||||||||||||||||||||||||||
| January 1, 2014 |
Total gains / losses in income statement 1 |
Total gains / losses in OCI 2 |
Purchases | Sales | Settlements | Net exchange differences |
Reclassification | Transfers from Level I and Level II |
Transfers to Level II |
June 30, 2014 |
Total unrealized gains and losses for the period recorded in the P&L for instruments held at June 30, 2014 ³ |
|||||||||||||||||||||||||||||||||||||
| Financial assets carried at fair value available-for-sale investments |
||||||||||||||||||||||||||||||||||||||||||||||||
| Shares |
322 | 36 | (14 | ) | 29 | (101 | ) | - | 1 | - | - | (1 | ) | 271 | - | |||||||||||||||||||||||||||||||||
| Debt securities |
3,162 | 13 | 79 | 665 | (157 | ) | (95 | ) | 12 | - | 123 | (503 | ) | 3,299 | - | |||||||||||||||||||||||||||||||||
| Other investments at fair value |
826 | (51 | ) | (12 | ) | 72 | (29 | ) | (4 | ) | 5 | - | 17 | - | 824 | - | ||||||||||||||||||||||||||||||||
| 4,310 | (2 | ) | 53 | 765 | (287 | ) | (99 | ) | 18 | - | 140 | (503 | ) | 4,395 | - | |||||||||||||||||||||||||||||||||
| Fair value through profit or loss |
||||||||||||||||||||||||||||||||||||||||||||||||
| Debt securities |
17 | 1 | - | 20 | - | (9 | ) | - | - | - | - | 30 | 2 | |||||||||||||||||||||||||||||||||||
| Other investments at fair value |
1,217 | 49 | - | 16 | (145 | ) | - | 8 | - | 64 | (14 | ) | 1,195 | 49 | ||||||||||||||||||||||||||||||||||
| Investments for account of policyholders |
1,989 | 45 | - | 224 | (258 | ) | - | 9 | - | 98 | (161 | ) | 1,947 | 42 | ||||||||||||||||||||||||||||||||||
| Derivatives |
328 | (62 | ) | - | - | (14 | ) | - | 4 | 44 | - | - | 299 | (79 | ) | |||||||||||||||||||||||||||||||||
| 3,552 | 33 | - | 261 | (417 | ) | (9 | ) | 20 | 44 | 162 | (175 | ) | 3,471 | 14 | ||||||||||||||||||||||||||||||||||
| Financial liabilities carried at fair value |
||||||||||||||||||||||||||||||||||||||||||||||||
| Investment contracts for account of policyholders |
114 | 2 | - | - | - | - | 1 | - | - | - | 117 | 2 | ||||||||||||||||||||||||||||||||||||
| Derivatives |
1,431 | 421 | - | - | 16 | - | 1 | 44 | - | - | 1,913 | 412 | ||||||||||||||||||||||||||||||||||||
| 1,545 | 423 | - | - | 16 | - | 2 | 44 | - | - | 2,030 | 414 | |||||||||||||||||||||||||||||||||||||
1 Includes impairments and movements related to fair value hedges. Gains and losses are recorded in the line item results from financial transactions of the income statement.
2 Total gains and losses are recorded in line items Gains/ (losses) on revaluation of available-for-sale investments and (Gains)/ losses transferred to the income statement on disposal and impairment of available-for-sale investment of the statement of other comprehensive income.
3 Total gains / (losses) for the period during which the financial instrument was in Level III.
During the first six months of 2014, Aegon transferred certain financial instruments from Level II to Level III of the fair value hierarchy. The reason for the change in level was that the market liquidity for these securities decreased, which led to a change in market observability of prices. Prior to transfer, the fair value for the Level II securities was determined using observable market transactions or corroborated broker quotes respectively for the same or similar instruments. The amount of assets and liabilities transferred to Level III was EUR 302 million (full year 2013: EUR 785 million). Since the transfer, all such assets have been valued using valuation models incorporating significant non market-observable inputs or uncorroborated broker quotes.
Similarly, during the first six months of 2014, Aegon transferred certain financial instruments from Level III to other levels of the fair value hierarchy. The change in level was mainly the result of a return of activity in the market for these securities and that for these securities the fair value could be determined using observable market transactions or corroborated broker quotes for the same or similar instruments. Transfers from Level III amounted to EUR 678 million (full year 2013: EUR 756 million).
| Unaudited | 21 |
The table below presents information about the significant unobservable inputs used for recurring fair value measurements for certain Level III financial instruments.
| Overview of significant unobservable inputs | ||||||||||||||||
| EUR millions | Carrying amount June 30, 2014 |
Valuation technique 1 | Significant unobservable input 2 |
Range (weighted average) | ||||||||||||
| Financial assets carried at fair value available-for- |
||||||||||||||||
| Shares |
127 | Broker quote | n.a. | n.a. | ||||||||||||
| 144 | Other | n.a. | n.a. | |||||||||||||
| 271 | ||||||||||||||||
| Debt securities |
||||||||||||||||
| 2,681 | Broker quote | n.a. | n.a. | |||||||||||||
| 130 | Discounted cash flow | Discount rate | 3% - 8% (6.93%) | |||||||||||||
| 199 | Discounted cash flow | Credit spread | 0.8% - 3.4% (2.44%) | |||||||||||||
| 291 | Other | n.a. | n.a. | |||||||||||||
| 3,299 | ||||||||||||||||
| Other investments at fair value |
||||||||||||||||
| Tax credit investments |
673 | Discounted cash flow | Discount rate | 8.6% | ||||||||||||
| Investment funds |
99 | Net asset value | n.a. | n.a. | ||||||||||||
| Other |
52 | Other | n.a. | n.a. | ||||||||||||
| 824 | ||||||||||||||||
| June 30, 2014 |
4,395 | |||||||||||||||
| Fair value through profit or loss |
||||||||||||||||
| Debt securities |
30 | Other | n.a. | n.a. | ||||||||||||
| 30 | ||||||||||||||||
| Other investments at fair value |
||||||||||||||||
| Investment funds |
1,165 | Net asset value | n.a. | n.a. | ||||||||||||
| Other |
30 | Other | n.a. | n.a. | ||||||||||||
| 1,195 | ||||||||||||||||
| Derivatives 3 |
||||||||||||||||
| Longevity swap |
108 | Discounted cash flow | Mortality | n.a. | ||||||||||||
| Other |
120 | Other | n.a. | n.a. | ||||||||||||
| 228 | ||||||||||||||||
| June 30, 2014 |
1,453 | |||||||||||||||
| Total financial assets at fair value 3 |
5,848 | |||||||||||||||
|
Financial liabilities carried at fair value |
||||||||||||||||
| Derivatives |
||||||||||||||||
| Embedded derivatives in insurance contracts |
1,745 | Discounted cash flow | Credit spread | 0.3% - 0.4% (0.34%) | ||||||||||||
| Other |
169 | Other | n.a. | n.a. | ||||||||||||
| Total financial liabilities at fair value |
1,913 | |||||||||||||||
| 1 | Other in the table above (column Valuation technique) includes investments for which the fair value is uncorroborated and no broker quote is received. |
| 2 | Not applicable (n.a.) has been included when no significant unobservable assumption has been identified and used. |
| 3 | Investments for account of policyholders are excluded from the table above and from the disclosure regarding reasonably possible alternative assumptions. Policyholder assets, and their returns, belong to policyholders and do not impact Aegon’s net income or equity. The effect on total assets is offset by the effect on total liabilities. Derivatives exclude derivatives for account of policyholders amounting to EUR 71 million. |
The description of Aegon’s methods of determining fair value is included in the consolidated financial statements for 2013. For reference purposes, the valuation techniques included in the table above are described in more detail on the following pages.
| 22 | Unaudited |
Shares
When available, Aegon uses quoted market prices in active markets to determine the fair value of its investments in shares. Fair values for unquoted shares are estimated using observations of the price/earnings or price/cash flow ratios of quoted companies considered comparable to the companies being valued. Valuations are adjusted to account for company-specific issues and the lack of liquidity inherent in an unquoted investment. Adjustments for illiquidity are generally based on available market evidence. In addition, a variety of other factors are reviewed by management, including, but not limited to, current operating performance, changes in market outlook and the third-party financing environment.
Available-for-sale shares include shares in a Federal Home Loan Bank (“FHLB”) for an amount of EUR 95 million (December 31, 2013: EUR 94 million) that are measured at par, which are reported as part of Other. A FHLB has implicit financial support from the United States government. The redemption value of the shares is fixed at par and they can only be redeemed by the FHLB.
Debt securities
Debt securities are comprised of residential mortgage-backed securities (RMBS), commercial mortgage-backed securities (CMBS), asset-backed securities (ABS), corporate bonds and sovereign debt. Details on the fair value measurement for these specific types of debt securities are provided below.
Valuations of RMBS, CMBS and ABS are monitored and reviewed on a monthly basis. Valuations per asset type are based on a pricing hierarchy which uses a waterfall approach that starts with market prices from indices and follows with third-party pricing services or brokers. The pricing hierarchy is dependent on the possibilities of corroboration of the market prices. If no market prices are available, Aegon uses internal models to determine fair value. Significant inputs included in the internal models are generally determined based on relative value analyses, which incorporate comparisons to instruments with similar collateral and risk profiles. Market standard models may be used to model the specific collateral composition and cash flow structure of each transaction. The most significant unobservable input is liquidity premium which is embedded in the discount rate. The weighted average liquidity premium used in valuation of ABS has increased to 6.93% (December 31, 2013: 6.62%). Broker quoted debt securities include ABS for an amount of EUR 2,261 million (December 31, 2013: EUR 2,030 million).
Valuations of corporate bonds are monitored and reviewed on a monthly basis. The pricing hierarchy is dependent on the possibility of corroboration of market prices when available. If no market prices are available, valuations are determined by a discounted cash flow methodology using an internally calculated yield. The yield is comprised of a credit spread over a given benchmark. In all cases, the benchmark is an observable input. The credit spread contains both observable and unobservable inputs. Aegon starts by taking an observable credit spread from a similar bond of the given issuer, and then adjusts this spread based on unobservable inputs. These unobservable inputs may include subordination, liquidity and maturity differences. The weighted average credit spread used in valuation of corporate bonds has increased to 2.44% (December 31, 2013: 2.33%).
When available, Aegon uses quoted market prices in active markets to determine the fair value of its sovereign debt investments. When Aegon cannot make use of quoted market prices, market prices from indices or quotes from third-party pricing services or brokers are used.
Tax credit investments
The fair value of tax credit investments is determined by using a discounted cash flow valuation technique. This valuation technique takes into consideration projections of future capital contributions and distributions, as well as future tax credits and the tax benefits of future operating losses. The present value of these cash flows is calculated by applying a discount rate. In general, the discount rate is determined based on the cash outflows for the investments and the cash inflows from the tax credits/tax benefits (and the timing of those cash flows). These inputs are unobservable in the market place. The discount rate used in valuation of tax credit investments has increased to 8.6% (December 31, 2013: 8.2%).
| Unaudited | 23 |
Investment funds
Investment funds include real estate funds, private equity funds and hedge funds. The fair values of investments held in non-quoted investment funds are determined by management after taking into consideration information provided by the fund managers. Aegon reviews the valuations each month and performs analytical procedures and trending analyses to ensure the fair values are appropriate.
Derivatives
Where quoted market prices are not available, other valuation techniques, such as option pricing or stochastic modeling, are applied. The valuation techniques incorporate all factors that a typical market participant would consider and are based on observable market data when available. Models are validated before they are used and calibrated to ensure that outputs reflect actual experience and comparable market prices.
Fair values for exchange-traded derivatives, principally futures and certain options, are based on quoted market prices in active markets. Fair values for over-the-counter (“OTC”) derivatives represent amounts estimated to be received from or paid to a third party in settlement of these instruments. These derivatives are valued using pricing models based on the net present value of estimated future cash flows, directly observed prices from exchange-traded derivatives, other OTC trades, or external pricing services. Most valuations are derived from swap and volatility matrices, which are constructed for applicable indices and currencies using current market data from many industry standard sources. Option pricing is based on industry standard valuation models and current market levels, where applicable. The pricing of complex or illiquid instruments is based on internal models or an independent third party. For long-dated illiquid contracts, extrapolation methods are applied to observed market data in order to estimate inputs and assumptions that are not directly observable. To value OTC derivatives, management uses observed market information, other trades in the market and dealer prices.
Some OTC derivatives are so-called longevity derivatives. The payout of longevity derivatives is linked to publicly available mortality tables. The derivatives are measured using the present value of the best estimate of expected payouts of the derivative plus a risk margin. The best estimate of expected payouts is determined using best estimate of mortality developments. Aegon determined the risk margin by stressing the best estimate mortality developments to quantify the risk and applying a cost-of-capital methodology. The most significant unobservable input for these derivatives is the (projected) mortality development.
Aegon normally mitigates counterparty credit risk in derivative contracts by entering into collateral agreements where practical and in ISDA master netting agreements for each of the Group’s legal entities to facilitate Aegon’s right to offset credit risk exposure. Changes in the fair value of derivatives attributable to changes in counterparty credit risk were not significant.
Embedded derivatives in insurance contracts including guarantees
All bifurcated guarantees for minimum benefits in insurance and investment contracts are carried at fair value. These guarantees include guaranteed minimum withdrawal benefits (GMWB) in the United States, United Kingdom and Japan which are offered on some variable annuity products and are also assumed from a ceding company; minimum investment return guarantees at end dates that are offered on universal life products sold in the Netherlands; and guaranteed minimum accumulation benefits on segregated funds sold in Canada.
Since the price of these guarantees is not quoted in any market, the fair values of these guarantees are calculated as the present value of future expected payments to policyholders less the present value of assessed rider fees attributable to the guarantees. Given the complexity and long-term nature of these guarantees which are unlike instruments available in financial markets, their fair values are determined by using stochastic techniques under a variety of market return scenarios. A variety of factors are considered including credit spread, expected market rates of return, equity and interest rate volatility, correlations of market returns, discount rates and actuarial assumptions. The most significant unobservable factor is credit spread. The credit spread used in the valuations of embedded derivatives in insurance contracts decreased to 0.34% (December 31, 2013: 0.47%).
| 24 | Unaudited |
The expected returns are based on risk-free rates. Aegon added a premium to reflect the credit spread as required. The credit spread is set by using the credit default swap (CDS) spreads of a reference portfolio of life insurance companies (including Aegon), adjusted to reflect the subordination of senior debt holders at the holding company level to the position of policyholders at the operating company level (who have priority in payments to other creditors). Aegon’s assumptions are set by region to reflect differences in the valuation of the guarantee embedded in the insurance contracts.
Since many of the assumptions are unobservable and are considered to be significant inputs to the liability valuation, the liability included in future policy benefits has been reflected within Level III of the fair value hierarchy.
Effect of reasonably possible alternative assumptions
The effect of changes in unobservable inputs on fair value measurement as reported in the 2013 consolidated financial statements of Aegon has not changed significantly as per June 30, 2014.
Fair value information about financial instruments not measured at fair value
The following table presents the carrying values and estimated fair values of financial assets and liabilities, excluding financial instruments which are carried at fair value on a recurring basis.
| Fair value information about financial instruments not measured at fair value
|
||||||||||||||||
| EUR millions | Carrying amount June 30, 2014 |
Total estimated fair value June 30, 2014 |
Carrying amount December 31, 2013 |
Total estimated fair value December 31, 2013 |
||||||||||||
| Assets |
||||||||||||||||
| Mortgage loans - held at amortized cost |
30,532 | 35,899 | 29,245 | 32,869 | ||||||||||||
| Private loans - held at amortized cost |
1,806 | 2,031 | 1,783 | 1,888 | ||||||||||||
| Other loans - held at amortized cost |
2,283 | 2,283 | 2,381 | 2,381 | ||||||||||||
| Liabilities |
||||||||||||||||
| Trust pass-through securities - held at amortized cost |
125 | 125 | 135 | 122 | ||||||||||||
| Subordinated borrowings - held at amortized cost |
739 | 807 | 44 | 73 | ||||||||||||
| Borrowings – held at amortized cost |
12,417 | 12,758 | 11,003 | 11,291 | ||||||||||||
| Investment contracts - held at amortized cost |
13,522 | 13,862 | 14,079 | 14,387 | ||||||||||||
Financial instruments for which carrying value approximates fair value
Certain financial instruments that are not carried at fair value are carried at amounts that approximate fair value, due to their short-term nature and generally negligible credit risk. These instruments include cash and cash equivalents, short-term receivables and accrued interest receivable, short-term liabilities, and accrued liabilities. These instruments are not included in the table above.
13. Deferred expenses
| EUR millions |
Jun. 30, 2014 | Dec. 31, 2013 | ||||||
| DPAC for insurance contracts and investment contracts with discretionary participation features |
9,161 | 9,229 | ||||||
| Deferred cost of reinsurance |
404 | 421 | ||||||
| Deferred transaction costs for investment management services |
365 | 356 | ||||||
| Total deferred expenses |
9,931 | 10,006 | ||||||
| Unaudited | 25 |
14. Share capital
| EUR millions |
Jun. 30, 2014 | Dec. 31, 2013 | ||||||
| Share capital - par value |
327 | 325 | ||||||
| Share premium |
8,374 | 8,375 | ||||||
| Total share capital |
8,701 | 8,701 | ||||||
| Share capital - par value |
||||||||
| Balance at January 1 |
325 | 319 | ||||||
| Issuance |
- | 84 | ||||||
| Withdrawal |
- | (82 | ) | |||||
| Share dividend |
2 | 5 | ||||||
| Balance |
327 | 325 | ||||||
| Share premium |
||||||||
| Balance at January 1 |
8,375 | 8,780 | ||||||
| Withdrawal |
- | (400 | ) | |||||
| Share dividend |
(2 | ) | (5 | ) | ||||
| Balance |
8,374 | 8,375 | ||||||
Basic and diluted earnings per share
| EUR millions |
Q2 2014 | Q2 2013 | YTD 2014 | YTD 2013 | ||||||||||||
| Earnings per share (EUR per share) |
||||||||||||||||
| Basic earnings per common share |
0.15 | 0.07 | 0.31 | 0.16 | ||||||||||||
| Basic earnings per common share B |
- | - | 0.01 | - | ||||||||||||
| Diluted earnings per common share |
0.15 | 0.07 | 0.31 | 0.16 | ||||||||||||
| Diluted earnings per common share B |
- | - | 0.01 | - | ||||||||||||
| Earnings per share calculation |
||||||||||||||||
| Net income attributable to equity holders of Aegon N.V. |
343 | 239 | 735 | 463 | ||||||||||||
| Preferred dividend |
- | (83 | ) | - | (83 | ) | ||||||||||
| Coupons on other equity instruments |
(37 | ) | (20 | ) | (83 | ) | (69 | ) | ||||||||
| Earnings attributable to common shares and common shares B |
306 | 136 | 652 | 311 | ||||||||||||
| Earnings attributable to common shareholders |
304 | 135 | 647 | 310 | ||||||||||||
| Earnings attributable to common shareholders B |
2 | 1 | 4 | 1 | ||||||||||||
| Weighted average number of common shares outstanding (in million) |
2,093 | 2,013 | 2,092 | 1,978 | ||||||||||||
| Weighted average number of common shares B outstanding (in million) |
580 | 299 | 579 | 150 | ||||||||||||
Diluted earnings per share is calculated by adjusting the average number of shares outstanding for share options. During the six months ended June 30, 2014, and during 2013, the average share price did not exceed the exercise price of these options. As a result, diluted earnings per share do not differ from basic earnings per share.
Dividend
The Annual General Meeting of Shareholders on May 21, 2014, approved a final dividend over 2013 payable in either cash or stock related to the second half of 2013, paid in the first half of 2014. The cash dividend amounted to EUR 0.11 per common share, the stock dividend amounted to one new Aegon common share for every 59 common shares held. The stock dividend and cash dividend are approximately equal in value. Dividend paid on common shares B amounted to 1/40th of the dividend paid on common shares. Approximately 40% of shareholders elected to receive the stock dividend. The remaining 60% opted for cash dividend. To neutralize the dilutive effect of the 2013 final dividend paid in shares, Aegon executed a program to repurchase 14,488,648 common shares. Between June 20, 2014, and July 17, 2014, these common shares were repurchased at an average price of EUR 6.4300 per share.
At June 30, 2014, Aegon had repurchased 5,969,584 common shares at an average price of EUR 6.4474. The liability for the repurchase of the remaining 8,519,064 shares, valued at the closing share price of EUR 6.3740 at June 30, 2014, amounted to EUR 54 million.
| 26 | Unaudited |
15. Other equity instruments
On June 15, 2014, Aegon redeemed junior perpetual capital securities with a coupon of 7.25% issued in 2007. The junior perpetual capital securities were originally issued at par with a carrying value of EUR 745 million. The principal amount of USD 1,050 million (EUR 774 million) was repaid with accrued interest. The cumulative foreign currency result at redemption was recorded directly in retained earnings.
On March 15, 2014, Aegon redeemed junior perpetual capital securities with a coupon of 6.875% issued in 2006. The junior perpetual capital securities were originally issued at par with a carrying value of EUR 438 million. The principal amount of USD 550 million (EUR 396 million) was repaid with accrued interest. The cumulative foreign currency result at redemption was recorded directly in retained earnings.
16. Subordinated borrowings
On April 25, 2014, Aegon issued EUR 700 million of subordinated notes, first callable on April 25, 2024 and maturing on April 25, 2044. The coupon is fixed at 4% until the first call date and floating thereafter.
17. Borrowings
| EUR millions | Jun. 30, 2014 | Dec. 31, 2013 | ||||||
| Debentures and other loans |
12,983 | 11,830 | ||||||
| Commercial paper |
150 | 135 | ||||||
| Short-term deposits |
12 | 16 | ||||||
| Bank overdrafts |
296 | 39 | ||||||
| Total borrowings |
13,441 | 12,020 | ||||||
Debentures and other loans
Included in Debentures and other loans is EUR 1,024 million relating to borrowings measured at fair value (2013: EUR 1,017 million).
On March 13, 2014, Aegon executed a transaction under the Dutch SAECURE program to sell Class A mortgage backed securities (RMBS) amounting to EUR 1.4 billion. “SAECURE 14 NHG” consists of 2 tranches:
| t | EUR 343 million of class A1 notes with an expected weighted average life of 2 years and priced with a coupon of three month Euribor plus 0.40%; and |
| t | EUR 1,024 million of class A2 notes with an expected weighted average life of 5 years and priced with a coupon of three month Euribor plus 0.72%. |
Commercial paper, Short-term deposits and Bank overdrafts vary with the normal course of business.
| Unaudited | 27 |
18. Commitments and contingencies
In June, 2013, the Dutch Supreme Court denied Aegon’s appeal from a ruling of the Court of Appeal with respect to a specific Aegon unit-linked product, the “KoersPlan” product. As a result of the Dutch Supreme Court’s denial of appeal, Aegon compensated the approximately 35,000 holders of KoersPlan products who were plaintiffs in the litigation. Aegon has issued, sold or advised on approximately 600,000 KoersPlan products. In June 2014, Aegon announced that it would also compensate holders of KoersPlan-products that were not plaintiffs in the litigation. The compensation equals the excess, if any, of the premium actually charged by Aegon over the amount of premium charged by Aegon for stand-alone death benefit coverage for a comparable risk over the same period. The costs of this product improvement will be covered by existing provisions.
In March 2014, consumer interest group Vereniging Woekerpolis.nl filed a new claim against Aegon in court. The claim relates to a range of unit-linked products of Aegon, challenging a variety of elements of these products on multiple legal grounds. At this time it is not practicable for Aegon to quantify a range or maximum liability, if any.
Optas
Aegon and BPVH – a foundation representing Dutch harbor workers and employers – have reached an agreement on removing restrictions on the capital of the harbor workers’ former pension fund Optas. This agreement, announced on April 14, 2014, ends a dispute that began when the Optas pension fund was transformed into an insurance company that was subsequently acquired by Aegon in 2007.
In August Aegon expects to, jointly with BPVH, file a request with the Dutch court to remove the restriction on the capital of Optas. Upon the court granting this request, Aegon will make a payment of EUR 80 million to BPVH, as well as offering harbor workers more favorable pension terms. In addition, over the coming years Aegon will contribute up to EUR 20 million to help mitigate the effect of an announced reduction in the tax-free pension allowance in the Netherlands.
No amounts in respect of this agreement have been recognized in these condensed consolidated interim financial statements because the outcome of the request to the court to remove the restriction is uncertain.
There have been no other material changes in contingent assets and liabilities as reported in the 2013 consolidated financial statements of Aegon.
19. Acquisitions / divestments
There were no significant acquisitions or divestments during the six months ended June 30, 2014.
20. Events after the balance sheet date
On July 30, 2014, Aegon signed a new 25-year agreement to distribute both protection and general insurance products through Banco Santander’s approximately 600 branches in Portugal. Under the terms of the agreement, Aegon will acquire a 51% stake in Banco Santander’s Portuguese insurance activities. The transaction is subject to regulatory approval and expected to close in the fourth quarter of 2014.
| 28 | Unaudited |
Management Statement
The interim report for the six months ended June 30, 2014, consists of the Condensed Consolidated
Interim Financial Statements, the Q2 2014 results release and the responsibility statement by the Company’s Executive Board. The information in this interim report is unaudited.
The Executive Board is responsible for preparing the Condensed Consolidated Interim Financial Statements in accordance with Dutch law and IAS 34, Interim Financial Reporting, as adopted by the European Union.
The Executive Board declares that, to the best of its knowledge, the Condensed Consolidated Interim Financial Statements which have been prepared in accordance with lAS 34, “Interim Financial Reporting”, as adopted by the European Union, give a true and fair view of the assets, liabilities, financial condition and profit or loss of Aegon N.V. and the undertakings included in the consolidation as a whole and that the Q2 2014 results release includes a fair review of the information required pursuant to section 5:2Sd, subsections 8 and 9 of the Dutch Act on Financial Supervision (Wet op het financieel toezicht).
The Hague, August 13, 2014
A.R. Wynaendts
Chairman of the Executive Board and CEO
D.D. Button
Member of the Executive Board and CFO
| Unaudited | 29 |
To: The Supervisory Board and the Executive Board of Aegon N.V.
Review report
Introduction
We have reviewed the accompanying condensed consolidated interim financial statements for the six-month period ended June 30, 2014 of Aegon N.V., The Hague, as set out on pages 2 to 29, which comprises the condensed consolidated statement of financial position as at June 30, 2014, the condensed consolidated income statement, the condensed consolidated statement of comprehensive income, the condensed consolidated statement of changes in equity, the condensed consolidated cash flow statement and the notes to the condensed consolidated interim financial statements for the six-month period then ended. We have not reviewed the condensed consolidated income statement, the condensed consolidated statement of comprehensive income and the condensed consolidated statement of changes in equity for the three-month period ended as at June 30, 2014. Management is responsible for the preparation and presentation of these condensed consolidated interim financial statements in accordance with IAS 34, ‘Interim Financial Reporting’ as adopted by the European Union. Our responsibility is to express a conclusion on these condensed consolidated interim financial statements based on our review.
Scope
We conducted our review in accordance with Dutch law including standard 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Dutch auditing standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
Conclusion
Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated interim financial statements as at and for the six-month period ended June 30, 2014 are not prepared, in all material respects, in accordance with IAS 34, ‘Interim Financial Reporting’ as adopted by the European Union.
Amsterdam, August 13, 2014
PricewaterhouseCoopers Accountants N.V.
Original has been signed by
drs. R. Dekkers RA
| 30 | Unaudited |
Disclaimers
Cautionary note regarding non-IFRS measures
This document includes the following non-IFRS financial measures: underlying earnings before tax, income tax and income before tax. These non-IFRS measures are calculated by consolidating on a proportionate basis Aegon’s joint ventures and associated companies. The reconciliation of these measures to the most comparable IFRS measure is provided in note 3 ‘Segment information’ of Aegon’s Condensed Consolidated Interim Financial Statements. Aegon believes that these non-IFRS measures, together with the IFRS information, provide meaningful information about the underlying operating results of Aegon’s business including insight into the financial measures that senior management uses in managing the business.
Local currencies and constant currency exchange rates
This document contains certain information about Aegon’s results and financial condition presented in USD for the Americas and GBP for the United Kingdom, because those businesses operate and are managed primarily in those currencies. None of this information is a substitute for or superior to financial information about Aegon presented in EUR, which is the currency of Aegon’s primary financial statements.
Forward-looking statements
The statements contained in this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. The following are words that identify such forward-looking statements: aim, believe, estimate, target, intend, may, expect, anticipate, predict, project, counting on, plan, continue, want, forecast, goal, should, would, is confident, will, and similar expressions as they relate to Aegon. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Aegon undertakes no obligation to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which merely reflect company expectations at the time of writing. Actual results may differ materially from expectations conveyed in forward-looking statements due to changes caused by various risks and uncertainties. Such risks and uncertainties include but are not limited to the following:
| t | Changes in general economic conditions, particularly in the United States, the Netherlands and the United Kingdom; |
| t | Changes in the performance of financial markets, including emerging markets, such as with regard to: |
| – | The frequency and severity of defaults by issuers in Aegon’s fixed income investment portfolios; |
| – | The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in the value of equity and debt securities Aegon holds; and |
| – | The effects of declining creditworthiness of certain private sector securities and the resulting decline in the value of sovereign exposure that Aegon holds; |
| t | Changes in the performance of Aegon’s investment portfolio and decline in ratings of Aegon’s counterparties; |
| t | Consequences of a potential (partial) break-up of the euro or the potential independence of Scotland from the United Kingdom; |
| t | The frequency and severity of insured loss events; |
| t | Changes affecting longevity, mortality, morbidity, persistence and other factors that may impact the profitability of Aegon’s insurance products; |
| t | Reinsurers to whom Aegon has ceded significant underwriting risks may fail to meet their obligations; |
| t | Changes affecting interest rate levels and continuing low or rapidly changing interest rate levels; |
| t | Changes affecting currency exchange rates, in particular the EUR/USD and EUR/GBP exchange rates; |
| t | Changes in the availability of, and costs associated with, liquidity sources such as bank and capital markets funding, as well as conditions in the credit markets in general such as changes in borrower and counterparty creditworthiness; |
| t | Increasing levels of competition in the United States, the Netherlands, the United Kingdom and emerging markets; |
| t | Changes in laws and regulations, particularly those affecting Aegon’s operations, ability to hire and retain key personnel, the products Aegon sells, and the attractiveness of certain products to its consumers; |
| t | Regulatory changes relating to the insurance industry in the jurisdictions in which Aegon operates; |
| t | Changes in customer behavior and public opinion in general related to, among other things, the type of products also Aegon sells, including legal, regulatory or commercial necessity to meet changing customer expectations; |
| t | Acts of God, acts of terrorism, acts of war and pandemics; |
| t | Changes in the policies of central banks and/or governments; |
| t | Lowering of one or more of Aegon’s debt ratings issued by recognized rating organizations and the adverse impact such action may have on Aegon’s ability to raise capital and on its liquidity and financial condition; |
| t | Lowering of one or more of insurer financial strength ratings of Aegon’s insurance subsidiaries and the adverse impact such action may have on the premium writings, policy retention, profitability and liquidity of its insurance subsidiaries; |
| t | The effect of the European Union’s Solvency II requirements and other regulations in other jurisdictions affecting the capital Aegon is required to maintain; |
| t | Litigation or regulatory action that could require Aegon to pay significant damages or change the way Aegon does business; |
| t | As Aegon’s operations support complex transactions and are highly dependent on the proper functioning of information technology, a computer system failure or security breach may disrupt Aegon’s business, damage its reputation and adversely affect its results of operations, financial condition and cash flows; |
| t | Customer responsiveness to both new products and distribution channels; |
| t | Competitive, legal, regulatory, or tax changes that affect profitability, the distribution cost of or demand for Aegon’s products; |
| t | Changes in accounting regulations and policies or a change by Aegon in applying such regulations and policies, voluntarily or otherwise, may affect Aegon’s reported results and shareholders’ equity; |
| t | The impact of acquisitions and divestitures, restructurings, product withdrawals and other unusual items, including Aegon’s ability to integrate acquisitions and to obtain the anticipated results and synergies from acquisitions; |
| t | Catastrophic events, either manmade or by nature, could result in material losses and significantly interrupt Aegon’s business; and |
| t | Aegon’s failure to achieve anticipated levels of earnings or operational efficiencies as well as other cost saving and excess capital and leverage ratio management initiatives. |
Further details of potential risks and uncertainties affecting Aegon are described in its filings with the Netherlands Authority for the Financial Markets and the US Securities and Exchange Commission, including the Annual Report. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation, Aegon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Aegon’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
| Unaudited | 31 |
Corporate and shareholder information
| Headquarters | ||||
| Aegon N.V. | ||||
| P.O. Box 85 | ||||
| 2501 CB The Hague | ||||
| The Netherlands | ||||
| Telephone | + 31 (0) 70 344 32 10 | |||
| aegon.com | ||||
Group Corporate Communications & Investor Relations
| Media relations | ||||
| Telephone | + 31 (0) 70 344 89 56 | |||
| [email protected] | ||||
| Investor relations | ||||
| Telephone | + 31 (0) 70 344 83 05 | |||
| or | 877 548 96 68 - toll free, USA only | |||
| [email protected] | ||||
Publication dates quarterly results 2014 and 2015
| November 13, 2014 | Results third quarter 2014 | |||
| February 19, 2015 | Results fourth quarter 2014 | |||
| May 13, 2015 | Results first quarter 2015 | |||
| August 13, 2015 | Results second quarter 2015 | |||
| November 12, 2015 | Results third quarter 2015 | |||
Aegon’s Q2 2014 press release and Financial Supplement are available on aegon.com.
About Aegon
Aegon’s roots go back more than 150 years – to the first half of the nineteenth century. Since then, Aegon has grown into an international company, with businesses in more than 25 countries in the Americas, Europe and Asia. Today, Aegon is one of the world’s leading financial services organizations, providing life insurance, pensions and asset management. Aegon’s purpose is to help people take responsibility for their financial future. More information: aegon.com.